POLITICO
Get the POLITICO Influence newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Coalition for App Fairness
With Daniel Lippman and Zach Warmbrodt
VENUES STILL WAITING FOR CASH AFTER LOBBYING VICTORY: When the pandemic hit last year, concert and performing arts venues banded together to form the National Independent Venue Association, which spent months lobbying Congress to help them. They succeeded in December: Congress included a grant program for shuttered venues in the Covid relief.
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA (vibegron), in the Journal of Urology
Urovant Sciences, a wholly owned subsidiary of Sumitovant, announced today that the
Journal of Urology has published positive safety and efficacy data from the GEMTESA (vibegron) double-blind 40-week extension study with patient data over a total exposure of 52 weeks (NCT03583372) in the print version of the
Journal of Urology. The peer-reviewed publication is currently available online and the print article is scheduled to be published in the May issue of the journal.
The published analysis supports the safety and efficacy of GEMTESA for the treatment of overactive bladder (OAB) in patients with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.
American Urological Association Names Next Science and Quality Chair
News provided by
Share this article
Share this article
BALTIMORE, April 15, 2021 /PRNewswire/ Today, the American Urological Association (AUA) announced its Board of Directors has approved Matthew Nielsen, MD, MS, FACS, as the next chair of the AUA Science and Quality (S&Q) Council. Dr. Nielsen will assume the role of chair-elect on June 1, 2021 and begin his four-year term as chair on June 1, 2022.
Matthew Nielsen, MD, MS, FACS, the next chair of the AUA Science and Quality (S&Q) Council.
As chair, Dr. Nielsen will lead the AUA S&Q Council, providing strategic oversight to shape and execute on the broad science, quality and data agenda of the AUA to include the creation, dissemination and implementation of clinical guidelines and white papers; maintenance of the AUA Quality (AQUA) Registry; development and implementation of physician performance measures; advancement of patient safety initiatives; moni
#BTColumn – Fatherhood can be a vas deferens barbadostoday.bb - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from barbadostoday.bb Daily Mail and Mail on Sunday newspapers.
Stress incontinence surgery does not increased risk of pelvic cancers
Women undergoing surgery to treat stress urinary incontinence (SUI) are not at increased risk of developing pelvic cancers, according to a large-scale, population-based study in
The Journal of Urology
®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
In a very large population with extended follow-up, we found no increase in the risk of any pelvic malignancy in women who underwent stress urinary incontinence surgery. The vast majority of stress urinary incontinence procedures performed included transvaginal mesh.
Humberto R. Vigil, MD, MSc, Lead Author, University of Ottawa, Ont., Canada